189 related articles for article (PubMed ID: 18533158)
1. The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients.
Hajer GR; Dallinga-Thie GM; van Vark-van der Zee LC; Visseren FL
Atherosclerosis; 2009 Jan; 202(1):216-24. PubMed ID: 18533158
[TBL] [Abstract][Full Text] [Related]
2. Lipid-lowering therapy does not affect the postprandial drop in high density lipoprotein-cholesterol (HDL-c) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial.
Hajer GR; Dallinga-Thie GM; van Vark-van der Zee LC; Olijhoek JK; Visseren FL
Clin Endocrinol (Oxf); 2008 Dec; 69(6):870-7. PubMed ID: 18394022
[TBL] [Abstract][Full Text] [Related]
3. High-dose statin monotherapy versus low-dose statin/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: The PANACEA study.
Westerink J; Deanfield JE; Imholz BP; Spiering W; Basart DC; Coll B; Kastelein JJ; Visseren FL
Atherosclerosis; 2013 Mar; 227(1):118-24. PubMed ID: 23261174
[TBL] [Abstract][Full Text] [Related]
4. The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial.
Olijhoek JK; Hajer GR; van der Graaf Y; Dallinga-Thie GM; Visseren FL
J Cardiovasc Pharmacol; 2008 Aug; 52(2):145-50. PubMed ID: 18670365
[TBL] [Abstract][Full Text] [Related]
5. Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes.
Bozzetto L; Annuzzi G; Corte GD; Patti L; Cipriano P; Mangione A; Riccardi G; Rivellese AA
Atherosclerosis; 2011 Jul; 217(1):142-8. PubMed ID: 21481394
[TBL] [Abstract][Full Text] [Related]
6. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease.
Abel T; Fehér J; Dinya E; Eldin MG; Kovács A
Med Sci Monit; 2009 Dec; 15(12):MS6-11. PubMed ID: 19946244
[TBL] [Abstract][Full Text] [Related]
8. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
[TBL] [Abstract][Full Text] [Related]
9. Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome.
Averna M; Missault L; Vaverkova H; Farnier M; Viigimaa M; Dong Q; Shah A; Johnson-Levonas AO; Taggart W; Brudi P
Diab Vasc Dis Res; 2011 Oct; 8(4):262-70. PubMed ID: 21859750
[TBL] [Abstract][Full Text] [Related]
10. Effects of increasing doses of simvastatin on fasting lipoprotein subfractions, and the effect of high-dose simvastatin on postprandial chylomicron remnant clearance in normotriglyceridemic patients with premature coronary sclerosis.
van Wijk JP; Buirma R; van Tol A; Halkes CJ; De Jaegere PP; Plokker HW; van der Helm YJ; Castro Cabezas M
Atherosclerosis; 2005 Jan; 178(1):147-55. PubMed ID: 15585212
[TBL] [Abstract][Full Text] [Related]
11. Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins.
Geiss HC; Otto C; Hund-Wissner E; Parhofer KG
Atherosclerosis; 2005 May; 180(1):107-12. PubMed ID: 15823282
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.
Ballantyne CM; Hoogeveen RC; Raya JL; Cain VA; Palmer MK; Karlson BW;
Atherosclerosis; 2014 Jan; 232(1):86-93. PubMed ID: 24401221
[TBL] [Abstract][Full Text] [Related]
13. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
Jimenez JG; Rosen JB; Pirags V; Massaad R; Hanson ME; Brudi P; Triscari J
Diabetes Obes Metab; 2013 Jun; 15(6):513-22. PubMed ID: 23279632
[TBL] [Abstract][Full Text] [Related]
15. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P;
Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
[TBL] [Abstract][Full Text] [Related]
16. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia.
Masuda D; Nakagawa-Toyama Y; Nakatani K; Inagaki M; Tsubakio-Yamamoto K; Sandoval JC; Ohama T; Nishida M; Ishigami M; Yamashita S
Eur J Clin Invest; 2009 Aug; 39(8):689-98. PubMed ID: 19490064
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of cholesterol uptake inhibition added to statin therapy among subjects following a low-carbohydrate diet: a randomized controlled trial.
Chirinos JA; Williams MM; Bregman DB; Ashfaq H; Khayyam U; Iqbal N
Am Heart J; 2010 May; 159(5):918.e1-6. PubMed ID: 20435205
[TBL] [Abstract][Full Text] [Related]
18. Effects of ezetimibe add-on to statin therapy on adipokine production in patients with metabolic syndrome and stable vascular disease.
Gupta M; Szmitko PE; Tsigoulis M; Braga MF; Kajil M; Herjikaka S; Quan A; Teoh H; Verma S
J Cardiovasc Pharmacol; 2010 Sep; 56(3):241-5. PubMed ID: 20505518
[TBL] [Abstract][Full Text] [Related]
19. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
20. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
